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PCN98
COST-EFFECTIVENESS OF A EUROPEAN COMMUNITY-BASED 
INTERVENTION: “10,000 STEPS GHENT”
De Smedt D1, De Cocker K1, Cardon G1, De Bourdeaudhuij I1, Annemans L2
1Ghent University, Gent, Belgium; 2Ghent University—Brussels University, Ghent, Belgium
OBJECTIVES: Physical inactivity is linked with inverse health effects and chronic 
disease. The aim of this study was to evaluate the cost-effectiveness of the European 
community-based project “10,000 Steps Ghent.” a published comparative controlled 
trial showed that the intervention resulted in a signiﬁ cant decrease in sedentary time 
and a signiﬁ cant increase in step counts (896 steps/day) and self-reported walking time 
(66 minutes/week). METHODS: A Markov model, with a time horizon of 20 years 
and a cycle length of 1 year was designed in Excel to estimate the development of 
diabetes, cardiovascular events, and colorectal cancer. All individuals start in a health-
state free of events. The model transitions were age dependent and based on epidemio-
logical data. The effect of the intervention was based on published relative risk 
reductions (RRR) related to increased walking time. Costs (from a public payer per-
spective) and utility decrements related to events were obtained from published litera-
ture. To assess the impact of the uncertainty of the parameters on incremental costs 
and QALYs one-way sensitivity analyses and a Monte Carlo analysis were performed. 
RESULTS: Implementing the community-based program increased average QALYs 
with 0.14 to 12.50 QALY and decreased the total costs with approximately c490 to 
c2749. Hence, the intervention program was dominant. One-way sensitivity analyses 
indicated that relative risk reductions had the most pronounced effect on the incre-
mental QALYs and costs, however without changing the conclusion of dominance. 
The results of the Monte Carlo analysis were favorable as well and the intervention, 
based on 5000 simulations, remained dominant. CONCLUSIONS: The community-
based “10,000 Steps Ghent” campaign is a dominant intervention. Sensitivity analyses 
have proved the robustness of the results; hence, implementing this intervention on a 
population-based level could lead to improved health outcomes and reduced costs.
PCN99
COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR 
RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS 
BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE
El Ouagari K1, Pawar V2, Coombs J3, Rubin J2
1Novartis Pharmaceuticals Canada, Dorval, QC, Canada; 2i3 Innovus, Medford, MA, USA; 
3Novartis, Florham Park, NJ, USA
OBJECTIVES: Clinical studies have highlighted the high risk of recurrence following 
complete resection of primary GIST. Published data from the phase III (ACOSOG 
Z9001) trial have demonstrated signiﬁ cant clinical beneﬁ t with adjuvant imatinib 
versus placebo with respect to recurrence-free survival (RFS 98% vs. 83% at 1 year). 
We conducted a health economic evaluation for imatinib as adjuvant therapy for GIST 
that can be used to support this indication. METHODS: A Markov model was used 
to project lifetime outcomes and costs for patients who undergo complete gross resec-
tion of primary GIST. Cost-effectiveness was measured in terms of the incremental 
cost per quality-adjusted life-year (QALY) gained with the addition of imatinib. Prob-
abilities of disease recurrence, resource use, utilities, and costs were derived from 
ACOSOG Z9001 trial and other secondary sources. Results were generated under 
three scenarios regarding the treatment duration with imatinib: 1-year, 3-year, and 
continuous treatment with imatinib. RESULTS: Adding imatinib was projected to 
result in a gain of 0.745, 1.538, and 5.180 QALYs assuming 1-year, 3-year, and 
continuous treatment scenarios, respectively. These clinical beneﬁ ts of imatinib are 
obtained at an additional expected per-patient lifetime cost of $30,042, $81,125, and 
$345,360 assuming 1-year, 3-year, and continuous treatment scenarios, respectively. 
The incremental cost per QALY gained with imatinib was therefore $40,328, $52,760, 
and $66,669 assuming 1-year, 3-year, and continuous treatment scenarios, respec-
tively. Deterministic sensitivity analyses showed the results to be robust with respect 
to variations in assumptions and estimates. The probability that imatinib is cost-
effective given a threshold value of $100,000 per QALY was over 98% in all scenarios. 
CONCLUSIONS: Results of this evaluation suggest that, from a Canadian health-care 
system perspective, imatinib is cost-effective and represents good value for the money 
according to currently accepted standards of cost-effectiveness.
PCN100
COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET 
CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL 
LUNG CANCER (NSCLC) IN SWEDEN
Jacob J, Henriksson M, Brattström D
AstraZeneca Nordic MC, Södertälje, Sweden
OBJECTIVES: The IPASS study (NCT00322452) showed that in patients with EGFR 
mutation-positive tumors (EGFRm+), geﬁ tinib signiﬁ cantly increased progression-free 
survival (PFS) compared with doublet chemotherapy, reducing the risk of progression 
by 52% (HR 0.48, 95% CI 0.36 to 0.64, P < 0.001) and increasing median PFS by 
3.2 months (9.5 months vs. 6.3 months) for the ﬁ rst-line treatment of advanced non-
small cell lung cancer (NSCLC). The aim of the study reported here was to evaluate 
the cost-effectiveness of a clinically relevant treatment strategy with geﬁ tinib based on 
data from IPASS. The strategy with geﬁ tinib involves EGFR mutation testing prior to 
treatment, followed by selective geﬁ tinib treatment of EGFRm+ patients and doublet 
chemotherapy for EGFRm- patients and patients with unknown mutation status, and 
is compared to treating all patients with doublet chemotherapy without mutation 
testing. METHODS: A Markov model was developed to integrate IPASS study data 
with external data on costs and quality of life. The model estimated costs and QALYs 
from a lifetime horizon for each treatment strategy. The key clinical data inputs were 
event rates of PFS and overall survival data. Other important parameters, e.g., preva-
lence of EGFRm+, cost of EGFR-diagnostics, resource utilization, and utility estimates 
were retrieved from the literature. RESULTS: The test and treat strategy, including 
geﬁ tinib, was associated with a QALY gain of 0.0116 at an incremental cost of c300 
yielding a cost per QALY gained of c25,900. CONCLUSIONS: This cost-effectiveness 
analysis of the IPASS study demonstrates that testing patients for EGFR status, fol-
lowed by geﬁ tinib treatment for EGFR m+ patients is a cost-effective option compared 
to treating all patients with doublet chemotherapy in a Swedish setting.
PCN101
COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE 
TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID 
LEUKAEMIA IN RUSSIA
Kuznetzov S1, Mungapen LJ2, Samyshkin Y2, Jakouloff DE3, Sbarigia U4, van Baardewijk M4
1Haematology Research Centre, Moscow, Russia; 2IMS Health, London, UK; 3BMS, Moscow, 
Russia; 4BMS, Braine l’Alleud, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of dasatinib 100 mg once daily in 
second-line therapy for chronic myeloid leukemia (CML) patients in the chronic phase 
(CP) resistant to imatinib 400 mg compared with imatinib 800 mg and nilotinib 
800 mg in Russia. METHODS: A Markov cost-utility model was developed to esti-
mate lifetime outcomes and resource use reﬂ ecting treatment practice for CML patients 
in Russia. Treatment efﬁ cacy, disease progression, and rates of adverse events in the 
model were based on published multicenter randomized controlled trials. RESULTS: 
Dasatinib appeared to be dominant over imatinib and nilotinib in CP-CML in the 
Russian setting. Incremental life expectancies were 0.17 years and 0.26 years when 
comparing dasatinib with imatinib and nilotinib, respectively; quality-adjusted life-
years (QALYs) gains were of 0.18 and 0.22 QALY versus imatinib and nilotinib, 
respectively. The life-years and QALY gains on dasatinib treatment were due to a 
larger proportion of patients who achieved complete cytogenic response (CCyR). 
Mean cost saving per patient over a lifetime horizon with dasatinib were Rubles (RUB) 
1,364,220 versus imatinib and RUB 778,621 versus nilotinib. Limitations of the model 
include a lack of direct comparative efﬁ cacy data at licensed doses, which precluded 
formal indirect comparison. CONCLUSIONS: Dasatinib was a dominating strategy, 
resulting in outcome gains (greater life expectancy and greater quality-adjusted life 
expectancy) and cost saving compared both to nilotinib and high-dose imatinib in 
CP-CML patients. Expanding access to new tyrosine kinase inhibitors for the treat-
ment of CP-CML in Russia would ensure a greater choice of modern and effective 
therapies.
PCN102
COST-EFFECTIVENESS OF DIGITAL MAMMOGRAPHY IN A BREAST 
CANCER POPULATION-BASED SCREENING PROGRAM
Comas M1, Arrospide A2, Mar J2, Roman R1, Sala M1, Hernandez C1, Castells X
1Hospital del Mar-IMIM, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, 
Spain; 2Hospital Alto Deba, Mondragon, Spain
OBJECTIVES: The introduction of digital mammography presents beneﬁ ts at the 
technological. However, there are doubts about its impact on the effectiveness of 
breast cancer screening. The aim of this study was to analyze the cost-effectiveness of 
the introduction of digital mammography in a population-based breast cancer screen-
ing program. METHODS: A discrete-event simulation model was implemented includ-
ing the processes under a breast cancer screening program and the natural history of 
breast cancer. The screening events included: invitation (biennial) of the target popula-
tion (women aged 50–69 years), participation, screening test, conﬁ rmatory tests after 
a positive mammography result, cancer diagnosis, and treatment. Natural history of 
breast cancer included the following health states: no cancer, preclinical (nonsymp-
tomatic) cancer, clinical (or symptomatic) cancer, and death. Natural history was 
modeled as time until a change of health state, and health states were managed using 
attributes in order to condition the sensitivities and speciﬁ cities of the tests to the 
current health state of the woman. Interval cancers were also detected according to 
the health state. Digital and analogical mammography had the same sensitivity, but 
different speciﬁ cities were applied according to type of mammography and also initial 
or successive screening. Cost-effectiveness was calculated under a 20-year screening 
scenario and ﬁ ve simulations. RESULTS: Simulation started with a target population 
of 28,020 women. Other 29,552 women were enrolled in the target population during 
the simulated 20 years. This population resulted in 56,136 screening mammograms. 
The number conﬁ rmatory tests needed was 1864 under analogical mammography and 
1724 under digital screening. Screen-detected cancers were 344 with analogical screen-
ing and 312 with digital screening. The overall ICER was c349.14. CONCLUSIONS: 
Results suggest that population-based breast cancer screening with digital mammog-
raphy is cost-effective. It does not improve the results of conventional analogical 
mammography, but it reduces the cost in conﬁ rmatory tests.
PCN103
COST-EFFECTIVENESS ANALYSIS OF ADDING HPV VACCINATION TO 
CERVICAL CANCER SCREENING PROGRAM IN HUNGARY
Vokó Z1, Nagyjanosi L2, Kalo Z1
1Eötvös Loránd University, Budapest, Hungary; 2Syreon Research Institute, Budapest, Hungary
OBJECTIVES: Despite opportunistic and organized screening, mortality of cervical 
cancer is still high in Hungary in international comparison. The study aimed to 
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investigate the cost-effectiveness of including HPV vaccination in the preventive strat-
egy of cervical cancer. METHODS: We developed an interactive Markov model based 
on modeling disease progression. Data on prevalences, incidences, test characteristics, 
efﬁ cacy of vaccination and of cancer treatments, and quality of life of cervical cancer 
patients were taken from the scientiﬁ c literature. Data on the costs of screening and 
of cancer treatments were provided by the Hungarian National Health Fund. We 
applied 5% discount rate for both cost and utility values. The effect of herd immunity 
was taken into account in the model. GDP PPP exchange rate in 2009 was employed 
to convert local currency to EUR (1 EUR = 158 HUF). RESULTS: We analyzed the 
cost-effectiveness of different scenarios. In case of the most likely scenario to come 
through—vaccination at age 12, coverage 80%, vaccine effectiveness against 
HPV16/18 (responsible for 72% of cervical cancers caused by HPV) being 95%, 
vaccine is efﬁ cient for at least 20 years, the effectiveness of the screening program is 
not improved radically—the ICER for vaccination was c49,587/QALY compared to 
no screening. CONCLUSIONS: As disease burden of cervical cancer is high in 
Hungary, including HPV vaccination in the preventive strategy of cervical cancer 
would result in a cost-effectiveness ratio below the implicit upper threshold (3× GDP/
capita = c49,986 in PPP).
PCN104
SOCIETAL COST SAVINGS IN METASTATIC NON-SMALL CELL LUNG 
CANCER (NSCLC) IN FRANCE
Stanisic S1, Vergnenegre A2, Chouaid C3, Mueller E1, Walzer S4
1Analytica International Inc., Loerrach, Germany; 2SIME, Limoges, France; 3Hôpital St. Antoine, 
Paris, France; 4F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: Bevacizumab in combination with platinum-based chemotherapy 
improves progression-free survival (PFS) over chemotherapy alone in advanced or 
metastatic NSCLC. The aim of this analysis was to assess potential cost savings for 
society derived from the clinical beneﬁ ts of bevacizumab-based therapy in metastatic 
NSCLC patients returning to work in France. METHODS: Indirect cost calculation 
was performed using human capital approach in the population of progression free 
metastatic NSCLC patients. Clinical outcomes in terms of PFS from the two bevaci-
zumab phase III trials (Reck et al. 2009, Sandler et al. 2006) were applied to the 
incidence cases of nonsquamous metastatic NSCLC patients in France, taking into 
account only age groups eligible to work. Clinical experts were consulted to estimate 
the percentage of PFS patients who return to work after the induction phase. It was 
estimated that 20% of PFS patients, below 55 years of age and with performance 
status 0–1 would maintain their prior employment status (60% part time, 40% full 
time). Cost savings were analyzed for 1 year and 1.5 year time horizons applying 
French labor costs. RESULTS: Indirect cost savings per patient returning to work were 
c21,667 at year 1 and c39,001 at year 1.5. a change in employment pattern (40% 
part time, 60% full time) led to an approximate 14% increase of savings for both 
time horizons (c24,763 at year 1 and c44,573 at year 1.5). a 10% alteration of labor 
cost in either direction resulted in cost savings that were 10% higher/lower. CON-
CLUSIONS: Bevacizumab-based therapy could result in considerable cost savings in 
progression-free NSCLC patients. This societal economic beneﬁ t adds to the patients’ 
clinical beneﬁ t of increased survival outcomes.
PCN105
COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY 
IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER 
(NSCLC) IN GERMANY
Schmidt E1, Bischoff HG2, Heigener DF3, Stanisic S1, Walzer S4
1Analytica International Inc., Loerrach, Germany; 2Thoraxklinik Heidelberg GmbH, Hedelberg, 
Germany; 3Krankenhaus Grosshansdorf, Grosshansdorf, Germany; 4F. Hoffmann-La Roche 
Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: First-line treatment of advanced or metastatic NSCLC patients with 
bevacizumab demonstrated signiﬁ cantly improved progression-free survival (PFS) when 
added to platinum-based chemotherapy (Reck 2009; Sandler 2006). The aim of this 
analysis was to investigate whether this clinical beneﬁ t would translate into cost savings 
due to reduced productivity losses in metastatic NSCLC patients who return to work 
while treated with bevacizumab-based therapy in Germany. METHODS: Potential cost 
savings were calculated on the basis of reduced productivity losses for patients returning 
back to work during PFS periods of 1 and/or 1.5 years, applying the human capital 
approach. The percentage of progression-free patients with ECOG performance status 
0 and 1 was derived from the two bevacizumab phase III trials. Epidemiologic data as 
well as country-speciﬁ c employment rates were applied stepwise to estimate the meta-
static NSCLC patient population eligible to work and employed at diagnosis. It was 
assumed that 20% of progression-free patients would return to work after the induction 
phase while maintaining their prior employment status (40% full time). Cost savings 
related to productivity losses were calculated by applying German labor cost data to the 
derived population of interest. Results were weighted according to prescribing patterns 
of bevacizumab combination regimens (bevacizumab/cisplatin/gemcitabine or bevaci-
zumab/carboplatin/paclitaxel). Sensitivity analyses were performed for employment pat-
terns and labor cost. RESULTS: Mean cost savings were c21,171 at year 1 and c38,107 
at year 1.5 per progression-free patient returning to work in Germany. a change in 
employment pattern (60% full time) led to an approximate 14% increase of savings for 
both time horizons (c24,195 at year 1 and c43,551 at year 1.5). a 10% alteration of 
labor cost in either direction resulted in cost savings that were 10% higher/lower. 
CONCLUSIONS: In addition to its PFS beneﬁ ts bevacizumab-based therapy could result 
in considerable cost savings in progression free metastatic NSCLC patients.
PCN106
INDIRECT COST IN NON-SMALL CELL LUNG CANCER (NSCLC): A 
SYSTEMATIC LITERATURE REVIEW
Schmidt E1, Stanisic S1, Neumann M1, Walzer S2
1Analytica International Inc., Loerrach, Germany; 2F. Hoffmann-La Roche Pharmaceuticals AG, 
Basel, Switzerland
OBJECTIVES: Novel treatment options for NSCLC patients were shown to improve 
survival outcomes. Thus, it is of interest whether published evidence can be found on 
work productivity and employment consequences for this patient group and their 
informal caregivers, and on respective indirect cost data. METHODS: A systematic 
literature search from 1990 onward was performed using 19 bibliographic databases 
available via DIMDI (German Institute of Medical Documentation and Information), 
supplemented by searches for other publicly available sources such as abstracts at 
major health economic and clinical conferences, HTAs, and further gray literature. 
RESULTS: So far, published indirect cost data are elusive and rather limited to overall 
lung cancer. In lung cancer, indirect cost accounted for the major portion of total 
estimated cost, e.g., for Germany 78% (Ruff 2000) to 89% (Weißﬂ og 2001). Indirect 
costs per case seem to increase with stage. In an Australian study, overall stage IV 
lung cancer patients had direct and indirect costs that were 19% higher than the 
average (Bishop 2009). The only indirect cost information on advanced NSCLC was 
reported by Romanus (2008) for the United States (mean wage loss per newly diag-
nosed end-stage IV NSCLC patient was $1697 [$126–$3371] in the ﬁ rst few months 
after diagnosis) and by Perrone (2004) for Italy (mean productivity loss per patient 
of c60,263). Employment rates of NSCLC patients were reported to be about 13% 
of NSCLC stage IIIb or IV, treated with 2nd line chemotherapy in Italy (Gridelli 2007). 
In the same population, the informal care given by the principal caregiver was the 
main assistance cost item with average 3-month cost of c2368 representing 74% of 
total assistance cost. CONCLUSIONS: The indirect cost burden of NSCLC has 
scarcely been assessed so far and needs further quantitative investigation, particularly 
in view of the use of new treatment options.
PCN107
FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG 
CANCER (NSCLC) WITH BEVACIZUMAB AND SOCIETAL COST 
SAVINGS IN SPAIN
Stanisic S1, Castro Carpeño JD2, Walzer S3
1Analytica International Inc., Loerrach, Germany; 2La Paz University Hospital, Madrid, Spain; 
3F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: Bevacizumab-based therapy as ﬁ rst-line treatment of advanced or 
metastatic NSCLC is associated with longer progression-free survival (PFS) when 
compared with chemotherapy alone (Sandler et al. 2006; Reck et al. 2009). This study 
analyzes the implications of the clinical beneﬁ ts of bevacizumab-based treatment for 
the societal costs in Spain. METHODS: Clinical inputs (PFS) were obtained from two 
clinical trials (E4599 and AVAiL) comparing a bevacizumab regimen (combined with 
carboplatin/paclitaxel or cisplatin/gemcitabine) with chemotherapy alone. Percentage 
of patients returning to work was estimated as 20% of all progression-free patients 
with ECOG performance status 0–1 in the age of ≤55 years. PFS percentage was 
applied to the incidence estimation for nonsquamous metastatic NSCLC in Spain after 
applying speciﬁ c employment rate. Indirect costs were calculated using the human 
capital approach. Spanish labor costs available at EUROSTAT were applied after 
inﬂ ating to 2009 values. Employment patterns were suggested by the clinical experts 
(full time/part time), and were applied to the estimation of patients returning to work. 
Time frames for the calculations were 12 months and 18 months. RESULTS: Average 
cost saving per progression-free patient was c12,401 at 12 months and c22,322 at 18 
months. Sensitivity analysis on changes in employment patterns from 40% full 
time/60% part time to 60% full time/40% part time increased cost savings per patient 
to c14,173 and c25,511 at 12 and 18 months, respectively. CONCLUSIONS: Treat-
ment with bevacizumab-based therapy results in the reduction of productivity losses 
due to improved clinical beneﬁ ts and hereby leads to considerable societal cost savings.
PCN108
SOCIETAL COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED 
TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
IN ITALY
Mueller E1, Nuijten M2, Ravera S3, Stanisic S1, Walzer S4
1Analytica International Inc., Loerrach, Germany; 2Ars Accessus Medica, LG Jisp, Amsterdam, 
The Netherlands; 3Roche S.p.A., Milano, Italy; 4F. Hoffmann-La Roche Pharmaceuticals AG, 
Basel, Switzerland
OBJECTIVES: The high societal cost of lung cancer derives mostly from productivity 
losses associated with premature retirement and premature mortality (Weißﬂ og et al. 
2001). Bevacizumab-based therapy is associated with signiﬁ cantly improved progres-
sion-free survival (PFS) over chemotherapy alone in patients with advanced or meta-
static NSCLC (Reck et al. 2009; Sandler et al. 2006), the most common form of lung 
cancer. The aim of this analysis was to assess the potential cost savings for Italy 
resulting from a higher number of progression-free metastatic NSCLC patients return-
ing to work while treated with bevacizumab-based therapy. METHODS: Productivity 
losses were calculated on the basis of number of days lost due to illness. Country labor 
costs and employment rates were taken from EUROSTAT. It was assumed, based on 
expert opinion, that 20% of progression-free patients with ECOG performance status 
0–1 and eligible to work would go back to their original employment status after the 
induction therapy. The percentage of PFS patients was calculated from two clinical 
